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Abstract 
MYCN amplification drives one in six cases of neuroblastoma. The supernumerary gene copies 
are commonly found on highly rearranged, extrachromosomal circular DNA. The exact 
amplicon structure has not been described thus far and the functional relevance of its 
rearrangements is unknown. Here, we analyzed the MYCN amplicon structure and its chromatin 
landscape. This revealed two distinct classes of amplicons which explain the regulatory 
requirements for MYCN overexpression. The first class always co-amplified a proximal 
enhancer driven by the noradrenergic core regulatory circuit (CRC). The second class of MYCN 
amplicons was characterized by high structural complexity, lacked key local enhancers, and 
instead contained distal chromosomal fragments, which harbored CRC-driven enhancers. Thus, 
ectopic enhancer hijacking can compensate for the loss of local gene regulatory elements and 
explains a large component of the structural diversity observed in MYCN amplification. 
 
Introduction 
Oncogene amplification is a hallmark of cancer genomes. It leads to excessive proto-oncogene 
overexpression and is a key driver of oncogenesis. The supernumerary gene copies come in two 
forms, i. self-repeating arrays on a chromosome (homogeneously staining regions, HSR) and 
ii. many individual circular DNA molecules (extrachromosomal DNA, ecDNA, alias double 
minute chromosomes, dmin)1. EcDNA can arise during genome reshuffling events like 
chromothripsis and are subsequently amplified2,3. This partially explains why such circular 
DNAs can consist of several coding and non-coding distant parts of one or more chromosomes4. 
Over time, amplified DNA acquires additional internal rearrangements as well as coding 
mutations, which can confer adaptive advantages such as resistance to targeted therapy5-7. 
EcDNA re-integration into chromosomes can lead to intrachromosomal amplification as 
HSRs8,9 and act as a general driver of genome remodeling10. Our knowledge of the functional 
relevance of non-coding regions co-amplified on ecDNA, however, is currently limited. 
MYCN amplification is a prototypical example of a cancer-driving amplification. The 
developmental transcription factor was identified as the most commonly amplified gene in a 
recent pediatric pan-cancer study11. Its most prominent role is in neuroblastoma, a pediatric 
malignancy of the sympathetic nervous system. MYCN amplification characterizes one in six 
cases and confers dismal prognosis12. In contrast to long-term survival of more than 80% for 
non-amplified cases, 5-year overall survival is as low as 32% for MYCN-amplified 
neuroblastoma12. In these cases, MYCN amplification is likely an early driver of neuroblastoma 
formation. Accordingly, MYCN overexpression is sufficient to induce neuroblastic tumor 
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formation in mice13,14. Despite its central role in neuroblastoma biology, the epigenetic 
regulation of MYCN is incompletely understood.  
Recently, studies have identified a core regulatory circuit (CRC) including half a dozen 
transcription factors that drive a subset of neuroblastoma with noradrenergic cell identity, 
including most MYCN-amplified cases15-18. The epigenetic landscape around MYCN is less well 
described. In part, this is due to the structural complexity of MYCN amplicons and difficulties 
in the interpretation of epigenomic data in the presence of copy number variation. Recent 
evidence has emerged suggesting that local enhancers may be required for proto-oncogene 
expression on amplicons19. Here, we sought out to identify key regulatory elements near MYCN 
in neuroblastoma by integrating short- and long-read genomic and epigenomic data from 
neuroblastoma cell lines and primary tumors. We investigated the activity of regulatory 
elements in the context of MYCN amplification and characterized the relationship between 
amplicon structure and epigenetic regulation.  
 
Results 
Local CRC-driven enhancers contribute to MYCN expression in neuroblastoma  
In order to identify candidate regulatory elements near MYCN, we examined public H3K27ac 
chromatin immunoprecipitation and sequencing (ChIP-seq) and RNA sequencing (RNA-seq) 
data from 25 neuroblastoma cell lines15. ChIP-seq data for amplified genomic regions are 
characterized by a very low signal-to-noise ratio, which has complicated their interpretation in 
the past16. We therefore focused our analysis on 12 cell lines lacking MYCN-amplifications but 
expressing MYCN at different levels, allowing for the identification of MYCN-driving 
enhancers in neuroblastoma. Comparison of composite H3K27ac signals of MYCN-expressing 
vs. non-expressing cell lines identified at least 5 putative enhancer elements (e1-e5) that were 
exclusively present in the vicinity of MYCN in cells expressing MYCN, thus likely contributing 
to MYCN regulation (Fig. 1, Supplementary Fig. 1a). Consistent with differential RNA 
expression, a strong differential H3K27ac peak was identified spanning the MYCN promotor 
and gene body (MYCNp; Fig. 1). The identified enhancers were not active in developmental 
precursor cells such as embryonic stem cells, neuroectodermal cells or neural crest cells 
(Supplementary Fig. 1b), suggesting these enhancers were specific for later stages of 
sympathetic nervous system development or neuroblastoma. Transcription factor ChIP-seq in 
MYCN-expressing cells confirmed that four of the enhancers (e1, e2, e4, e5) were bound by 
each of three noradrenergic neuroblastoma core regulatory circuit factors (PHOX2B, HAND2, 
GATA3; Fig. 1b). All but enhancer e3 harbored binding motifs for the remaining members of 
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the core regulatory circuit (ISL1, TBX2, ASCL1; Supplementary Fig. 1c) for which ChIP-seq 
data were unavailable. Additionally, all enhancers contained binding motifs for TEAD4, a 
transcription factor implicated in a positive feedback loop with MYCN in MYCN-amplified 
neuroblastoma20. Two of the enhancers (e1, e2) also harbored canonical E-boxes, suggesting 
binding of MYCN at its own enhancers (Supplementary Fig. 1c). Thus, a common set of CRC-
driven enhancers is found specifically in MYCN expressing neuroblastoma cells, indicating that 
MYCN expression is regulated by the CRC.  
 
Local enhancer co-amplification explains asymmetric MYCN amplicon distribution  
MYCN is expressed at the highest levels in neuroblastomas with MYCN amplifications 
(Supplementary Fig. 1d). It is unclear, however, to what extent enhancers are required for 
sustained MYCN expression on MYCN-containing amplicons. To address this, we mapped 
amplified genomic regions in a meta-dataset of copy-number variation in 240 MYCN-amplified 
neuroblastomas21. This revealed an asymmetric pattern of MYCN amplification (Fig. 2a, 
Supplementary Fig. 2). Intriguingly, a 290kb region downstream of MYCN was co-amplified in 
more than 90% of neuroblastomas, suggesting that MYCN amplicon boundaries were not 
randomly distributed, which is in line with recent reports in a smaller tumor cohort19 Notably, 
the consensus amplicon boundaries did not overlap with common fragile sites (Supplementary 
Fig. 2g), challenging a previous association found in ten neuroblastoma cell lines8. Regions of 
increased chromosomal instability alone are therefore unlikely to explain amplicon boundaries. 
Intriguingly, several MYCN-specific enhancers were found to be commonly co-amplified (Fig. 
2b). The distal MYCN-specific CRC-driven enhancer, e4, was part of the consensus amplicon 
region in 90% of cases. Randomizing amplicon boundaries around MYCN showed that e4 co-
amplification was significantly enriched on MYCN amplicons (empirical P=0.0003). Co-
amplification frequency quickly dropped downstream of e4, suggesting that MYCN-specific, 
CRC-driven enhancers are a determinant of MYCN amplicon structure and may be required for 
MYCN expression, even in the context of high-level amplification. 
 
Distal CRC-driven super enhancers are significantly co-amplified with MYCN in 
neuroblastoma  
We and others have previously described chimeric MYCN amplicons10 containing distal 
chromosomal fragments. We therefore systematically inspected MYCN-distal regions on 
chromosome 2 for signs of co-amplification. Distinct regions were statistically enriched for co-
amplification with MYCN (Fig. 2c). In line with previous reports22, significant co-amplification 
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of 19 protein-coding genes, including known neuroblastoma drivers such as ODC1, GREB1 
and ALK occurred in MYCN-amplified neuroblastoma. Intriguingly, co-amplification of distal 
CRC-driven super enhancers (SE) occurred in 23.3% of samples. Seven specific CRC-driven 
SEs were significantly co-amplified more often than expected by chance. Most of these SEs 
were found in gene-rich regions, precluding to determine whether genes or regulatory elements 
were driving co-amplification. One significantly co-amplified CRC-driven SE, however, was 
found in a gene-poor region in 2p25.2, where most co-amplified segments did not overlap 
protein-coding genes (Fig. 2c). This raised the question whether hijacking of such distal 
regulatory elements may explain co-amplification with MYCN.   
 
Enhancers remain functional on MYCN amplicons  
Based on our amplicon boundary analysis, two classes of MYCN amplicons could be 
distinguished in neuroblastoma, i. amplicons containing local MYCN-specific enhancers, 
including e4, (here referred to as class I amplicons; Fig. 3a) and ii. amplicons lacking local 
MYCN-specific enhancers, and at least lacking e4 (referred to as class II amplicons; Fig. 3b). 
To determine whether co-amplified enhancers were active, we acquired genomic (long- and 
short-read whole genome sequencing) and epigenomic (ATAC-seq and H3K4me1 and 
H3K27ac ChIP-seq) data for two neuroblastoma cell lines with class I amplicons (Kelly and 
NGP) and two neuroblastoma cell lines with class II amplicons (IMR-5/75 and CHP-212). 
Notably, H3K27ac signal-to-noise ratio was lower on MYCN amplicons than in non-amplified 
regions. While the fraction of reads in peaks on the amplicon did not clearly differ between the 
amplicon and randomly drawn genomic regions, we observed more peaks than for non-
amplified regions (Supplementary Fig. 3). These peaks were characterized by a lower relative 
signal compared to the amplicon background signal, indicating a larger variety of active 
regulatory regions on different MYCN amplicons. Using Nanopore long read-based de novo 
assembly, we reconstructed the MYCN neighborhood, confirming that MYCN and e4 were not 
only co-amplified in class I amplicons, but also lacked large rearrangements, which could 
preclude enhancer-promoter interaction (Supplementary Fig. 4-5). Enhancer e4 was 
characterized by increased chromatin accessibility and active enhancer histone marks as 
determined by ATAC-seq, H3K4me1 and H3K27ac ChIP-seq (Fig. 3c). Importantly, 4C 
chromatin conformation capture analysis showed that e4 spatially interacted with the MYCN 
promotor on the amplicon (Fig. 3c). Thus, e4 presents as a functional enhancer and appears to 
contribute to MYCN expression even in the context of class I MYCN amplification. 
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Super enhancer hijacking compensates for the loss of local enhancers on chimeric intra- and 
extrachromosomal circular MYCN amplicons  
In contrast to class I amplicons, class II amplicons did not include local enhancers, raising the 
possibility of alternative routes of MYCN regulation. The lack of a strong local regulatory 
element on class II amplicons and our observation of frequent co-amplification of distal SE 
(Fig. 2c), led us to hypothesize that ectopic enhancers might be recruited to enable MYCN 
expression in class II amplicons. In line with our hypothesis, primary neuroblastomas with class 
II amplicons were more likely to harbor complex amplifications containing more than one 
fragment (66.7% vs. 35.7%, Fisher’s Exact Test P=0.003; Fig. 3e). All class II amplicons co-
amplified at least one CRC-driven super enhancer element distal of MYCN. Some enhancers 
were recurrently found on class II amplicons, including an enhancer 1.2Mb downstream of 
MYCN that was co-amplified in 20.8% (5/24) of MYCN-amplified neuroblastomas, 2.1-fold 
higher than expected for randomized amplicons that include MYCN but not e4 (Fig. 3f). Thus, 
class II MYCN amplicons are of high chimeric structural complexity allowing for the 
replacement of local enhancers through hijacking of distal CRC-driven enhancers.  
To determine the structure and epigenetic regulation of class II amplicons in detail, we 
inspected long-read based de novo assemblies and short read-based reconstructions of IMR-
5/75 and CHP-212 MYCN amplicons. IMR-5/75 was characterized by a linear HSR class II 
MYCN amplicon, not including e3-e5 (Fig. 3b). Inspection of the IMR-5/75 MYCN amplicon 
structure revealed that the amplicon consisted of six distant genomic regions, which were joined 
together to form a large and complex chimeric amplicon (Fig. 4a-d). In line with enhancer 
hijacking, an intronic segment of ALK containing a large super enhancer, marked by H3K27ac 
modification and chromatin accessibility, was juxtaposed with MYCN on the chimeric 
amplicon. Similar to e4, this enhancer was bound by adrenergic CRC factors in non-amplified 
cells (Supplementary Fig. 6a). Notably, a CTCF-bound putative insulator was added to the 
amplicon by yet another distal fragment (Fig. 4a-c, Supplementary Fig. 6a). In CHP-212, MYCN 
is amplified on extrachromosomal circular DNA, as confirmed by fluorescence in situ 
hybridization (Supplementary Fig. 7). Both de novo assembly and short-read based 
reconstruction of the amplicon confirmed the circular MYCN amplicon structure independently 
(Fig. 4f-h). Similar to IMR-5/75, distal fragments containing CRC-driven SEs and putative 
CTCF-bound insulators were joined to the MYCN neighborhood (Fig. 4e-g, Supplementary Fig. 
6b).  
To analyze the interaction profile in circular and linear amplicons we performed Hi-C and 
mapped the reads to the reconstructed amplicon (Fig. 4c, g). This analysis supported the 
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genomic sequencing-based reconstruction of the amplicon, recapitulating the order and 
orientation of the joined fragments and confirmed that the ectopic enhancers spatially interacted 
with MYCN. Notably, high-frequency interactions in the corners of the maps opposite to the 
main diagonal, confirmed the circularity of CHP-212 amplicon and the presence of tandem 
amplification in IMR-5/75. In IMR-5/75 and CHP-212, we observed insulated TADs, 
boundaries and loops as in the rest of the genome. Due to the rearrangements in CHP-212, the 
MYCN gene became part of a neo-TAD consisting of a sub-TAD that originated from the wild 
type genome as an intact unit, and a second sub-TAD that resulted from the fusion and co-
amplification of the first region with another region from a distal part of chromosome 2 
(chr2:12.6-12.8Mb), containing multiple CRC-driven SEs (Fig. 4g, Supplementary Fig. 6b). 
Since the fused segments are now part of one TAD and not separated by a boundary, MYCN 
interaction with the SEs in this region becomes possible. A similar situation was observed for 
the linear amplicon. In IMR-5/75, Hi-C showed frequent contacts between MYCN and SEs from 
the genomic regions juxtaposed to MYCN, containing intronic parts of ALK (Fig. 4c, 
Supplementary Fig. 6a). The map also reflected the high complexity and genomic heterogeneity 
of the IMR-5/75 amplicon. Nevertheless, the TAD structure, boundaries and loops were clearly 
visible on the reconstructed Hi-C map. Thus, hijacking of ectopic enhancers and insulators can 
compensate for the loss of endogenous regulatory elements on intra- and extrachromosomal 
circular MYCN amplicons via the formation of neo-TADs, which may explain the higher 
structural complexity of MYCN amplicons lacking endogenous enhancers.   
 
Nanopore long-read DNA sequencing can be used for parallel assessment of MYCN 
amplicon structure and epigenetic regulation  
In addition to allowing the alignment-free de novo assembly of the MYCN amplicon in several 
samples (Fig. 4b-d, f-h, Supplementary Fig. 4-5), Nanopore sequencing also allows for the 
direct measurement of DNA methylation without the need for bisulfite conversion (Fig. 5a)23. 
While DNA methylation at regulatory elements is often associated with repression, a trough in 
DNA methylation may indicate a transcription factor binding event, a poised or active gene 
regulatory element, or a CTCF-occupied insulator element (Fig. 5b). In theory, Nanopore 
sequencing and assembly might allow for the simultaneous inference of both structure and 
regulatory landscape (Fig. 5b). Prior to evaluating the MYCN amplicons, the DNA methylation 
landscape of highly expressed and inactive genes demonstrated the expected distribution of 
decreased methylation at active promoters and increased methylation within active gene bodies 
(Fig. 5c). In order to assess the DNA methylation status of putative regulatory elements near 
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MYCN, we first used the amplicon-enriched ATAC-seq peaks to classify relevant motif 
signatures (Fig. 5d). While MYCN was surrounded by the expected CRC-driven regulatory 
elements at the overlapping core enhancers as well as some CTCF sites, both their number and 
location varied, indicative of sample-specific sites of regulation. Indeed, DNA methylation 
decreased in accordance with sites specific to a given sample (Fig. 5e), opening up the 
possibility of using these data to infer regulatory elements in patient samples when no 
orthogonal epigenomic data are available. 
 
Class II MYCN amplicons clinically phenocopy class I amplicons  
MYCN-amplified neuroblastoma is characterized by significant clinical heterogeneity, which 
cannot entirely be explained genetically. Whether the structure of the MYCN amplicon itself 
could account for some of this variation is currently unknown. In line with previous reports22, 
higher counts of amplified fragments were associated with a more malignant clinical phenotype 
(Fig. 6a). Co-amplification of ODC1, a gene located 5.5Mb upstream of MYCN and co-
amplified in 9% (21/240) of MYCN-amplified neuroblastomas (Fig. 2c), defined an ultra-high 
risk genetical subgroup of MYCN-amplified neuroblastoma (HR 2.3 (1.4-3.7), Log-rank test 
P=0.001; Fig. 6b). Similarly, ALK co-amplification, present in in 5% (12/240) of MYCN-
amplified tumors, was also associated with adverse clinical outcome (HR 1.8 (0.94-3.4), Log-
rank test P=0.073; Fig. 6c). In contrast, differences in the MYCN amplicon enhancer structure, 
i.e. class II amplification, did not confer prognostic differences (HR 1.3 (0.78-2.1), Log rank 
test P=0.34; Fig. 6d). We therefore conclude that chimeric co-amplification of proto-oncogenes 
partly explain the malignant phenotype of neuroblastomas with complex MYCN amplicons, 
whereas enhancer hijacking in class II amplicons does not change clinical behavior, fully 
phenocopying class I MYCN amplicons.  
 
Discussion 
Here, we show that neuroblastoma-specific CRC-driven enhancers contribute to MYCN 
amplicon structure in neuroblastoma and retain the classic features of active enhancers after 
genomic amplification. While most MYCN amplicons contain local enhancers, ectopic 
enhancers are regularly incorporated into chimeric amplicons lacking local enhancers, leading 
to enhancer hijacking.  
A large subset of neuroblastomas was recently found to be driven by a small set of transcription 
factors that form a self-sustaining core regulatory circuit, defined by their high expression and 
presence of super-enhancers15-18. In how far MYCN itself is directly regulated by CRC factors 
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was previously unclear, particularly due to the challenging interpretation of epigenomic data on 
amplicons16. Our results provide empiric evidence that MYCN is driven by CRC factors even 
in the context of MYCN amplification. This is in line with and can mechanistically explain the 
previous observation that genetic depletion of CRC factors represses MYCN expression even in 
MYCN-amplified cells16. The finding that ectopic enhancers driven by the CRC are juxtaposed 
to MYCN on amplicons that lack local enhancers further strengthens the relevance of the CRC 
in MYCN regulation. 
In line with our observation of local enhancer co-amplification, Morton et al. recently described 
that local enhancers are significantly co-amplified with other proto-oncogenes in other cancer 
entities19. They showed that experimentally interfering with local EGFR enhancers in EGFR-
amplified glioblastoma impaired oncogene expression and cell viability in EGFR-amplified as 
well as non-amplified cases. In line with our findings, a region overlapping e4 was identified 
to be significantly co-amplified in MYCN-amplified neuroblastomas, corresponding to class I 
amplicons observed in our cohort. In contrast to Morton et al., who suggest that the inclusion 
of local enhancers is necessary for proto-oncogene expression on amplicons, we show that 
exceptions to this rule occur in a significant subset of MYCN amplified neuroblastomas. In such 
cases, amplicons are of highly complex chimeric structure enabling the reshuffling of ectopic 
enhancers and insulators to form neo-TADs that can compensate for disrupted local 
neighborhoods through enhancer hijacking.  
More generally, we show that TADs also form in ecDNA, in line with recent findings by Wu 
et al.24. We extend this observation to homogeneously staining regions, which form extremely 
expanded stretches of chromatin in interphase nuclei and lose chromosomal territoriality25. 
Gene activation by enhancer adoption requires the fusion of distant DNA fragments and the 
formation of new chromatin domains, called neo-TADs26. This fusion requires a convergent 
directionality of CTCF sites in order to form a new boundary. Only in this case, aberrant gene 
activation is possible27. 
Reconstruction of amplicons has previously relied on combining structural breakpoint 
coordinates to infer the underlying structure. This regularly resulted in ambiguous amplicon 
reconstructions, which had to be addressed by secondary data such as Chromium linked reads 
or optical mapping4,6,24. We demonstrate the feasibility of long-read de novo assembly for the 
reconstruction of amplified genomic neighborhoods. De novo assembly was able to reconstruct 
entire ecDNA molecules and confirm the tandem duplicating nature of homogeneously staining 
regions. Integrating de novo assembly with methylation data from Nanopore sequencing reads 
will likely benefit further studies of other proto-oncogene-containing amplicons by enabling 
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the characterization of the interplay between structure and regulation in highly rearranged 
cancer genomes.  
Functional studies have shown that both ODC1 and ALK are highly relevant in neuroblastoma 
28,29. Co-amplification with MYCN has been reported before22, but to our knowledge the clinical 
relevance of co-amplification had not been determined so far. Similar to our previous 
observations of PTP4A2 co-amplification on chimeric ecDNA10, we demonstrate here that 
proto-oncogenes reside side-by-side on the same extrachromosomal circular DNAs, sometimes 
even sharing the same regulatory neighborhood. It is tempting to speculate that this structural 
coupling of genes could confer MYCN-independent but MYCN-amplicon-specific, collateral 
therapeutic vulnerabilities in MYCN-amplified tumors. 
We conclude that the structure of genomic amplifications can be explained by selective pressure 
not only on oncogenic coding elements, but also on non-coding regulatory elements. CRC-
driven enhancers are required for successful MYCN amplification and remain functional 
throughout this process. Even though the majority of amplicons contain endogenous enhancers, 
these can be replaced by ectopic CRC-driven elements that are juxtaposed to the oncogene 
through complex chimeric amplicon formation. We envision that our findings also extend to 
oncogene amplifications in other cancers and will help identify functionally relevant loci 
amongst the diverse array of complex aberrations that drive cancer. 
 
Materials and Methods 
Cell lines 
Neuroblastoma cell lines (CHP-212, IMR-5/75, NGP, Kelly) were a gift from from Carol J. 
Thiele, obtained from the German Collection of Microorganisms and Cell Cultures or obtained 
from the American Type Culture Collection. Cell line identity was verified by STR genotyping 
(Genetica DNA Laboratories, Burlington, NC and IDEXX BioResearch, Westbrook, ME) and 
absence of Mycoplasma sp. contamination was determined with a Lonza MycoAlert system 
(Lonza Group Ltd., Basel, CH). All cell lines were cultured in RPMI-1640 medium (Thermo 
Fisher Scientific, Inc., Waltham, MA) with 1% Penicillin/Streptomycin, and 10% FCS. 
 
RNA-seq  
Public RNA-seq data was downloaded from Gene Expression Omnibus (GSE90683)15. FASTQ 
files were quality controlled (FASTQC 0.11.8) and adapters were trimmed (BBMap 38.58). We 
mapped reads to GRCh37 (STAR 2.7.1 with default parameters), counted them per gene 
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(Ensembl release 75, featureCounts from Subread package 1.6.4) and normalized for library 
size and composition (sizeFactors from DESeq2 1.22.2).  
 
ChIP-seq 
As reported before27, cells were digested with Trypsin–EDTA 0.05% (Gibco) for 10 min at 
37 °C. The cells were mixed with 10% FCS–PBS, and a single-cell suspension was obtained 
using a 40-µm cell strainer 30. After centrifugation, cells were resuspended in 10% FCS-PBS 
again and fixed in 1% paraformaldehyde (PFA) for 10 min at room temperature and reaction 
quenched with 2.5M glycine (Merck) on ice and centrifuged at 400g for 8min. Pelleted cells 
were then resuspended in lysis buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 5 mM EDTA; 0.5% 
NP-40; 1.15% Triton X-100; protease inhibitors (Roche)), and nuclei were pelleted again by 
centrifugation at 750g for 5min. For sonication, nuclei were resuspended in sonication buffer 
(10 mM Tris–HCl, pH 8.0; 100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0,1% Na-
deoxycholate; 0.5% N-lauroylsarcosine; protease inhibitors (Roche complete)). Chromatin was 
sheared using a Bioruptor until reaching a fragment size of 200–500 base pairs (bp). Lysates 
were clarified from sonicated nuclei, and protein–DNA complexes were immunoprecipitated 
overnight at 4 °C with the respective antibody. A total of 10–15 μg chromatin was used for each 
replicate of histone ChIP and 20-25µg of transcription factor ChIP. Anti-H3K27ac (Diagenode; 
c15410037; A1657D), anti-H3K4m1 (Abcam; ab8895; Lot A1657D), anti-RAD21 (Abcam; 
ab992; Lot GR221348-8) and anti-CTCF (Active Motif; 613111; Lot 34614003) antibodies 
were used. Sequencing libraries were prepared using standard Nextera adapters (Illumina) 
according to the supplier’s recommendations. 25 million reads per sample were sequenced on 
HiSeq 2500 sequencer (Illumina) in 50bp single read mode.  
Additional public ChIP-seq FASTQ files were downloaded from Gene Expression Omnibus 
(GSE90683, GSE24447 and GSE28874)15,31. FASTQ files were quality controlled (FASTQC 
0.11.8) and adapters were trimmed (BBMap 38.58). Reads were then aligned to hg19 (BWA-
MEM 0.7.15 with default parameters) and duplicate reads removed (Picard 2.20.4). We 
generated BigWig tracks by extending reads to 200bp for single-end libraries and extending to 
fragment size for paired-end libraries, filtering by ENCODE DAC blacklist and normalizing to 
counts per million in 10bp bins (Deeptools 3.3.0).  Peaks were called using MACS2 (2.1.2) 
with default parameters. Super enhancers were called for H3K27ac data using LILY 
(https://github.com/BoevaLab/LILY) with default parameters. ChIP-seq data was quality 
controlled using RSC and NSC (Phantompeakqualtools 1.2.1).  
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ATAC-seq  
ATAC-seq samples were processed as reported in Buenrostro et al32. 5x105 cells were used per 
sample. For sequencing, libraries were generated using Illumina/Nextera adapters and size 
selected (100–1000bp) with AMPure Beads (Beckman Coulter). Approximately 100 million 
75bp paired-end reads were acquired per sample on the HiSeq 2500 system (Illumina). 
Additional public ATAC-seq FASTQ files were downloaded from Gene Expression Omnibus 
(GSE80154)33. Adapter trimming, alignment and duplicate removal as for ChIP-seq. We 
generated BigWig tracks by extending paired-end reads to fragment size, filtering by the 
ENCODE DAC blacklist and normalizing to counts per million in 10bp bins (Deeptools 3.3.0).  
Peaks were called using MACS2 (2.1.2) with default parameters.  
 
Hi-C 
3C libraries for Hi-C and 4C were prepared from confluent neuroblastoma cells according to 
the cell culture section above. Hi-C experiments were performed as duplicates. Cells were 
washed twice with PBS and digested with Trypsin–EDTA 0.05% (Gibco) for 10 min at 37 °C. 
To obtain a single cell suspension, cells were pipetted through a 40-µm cell strainer 30. 
After centrifugation at 300g for 5min, cell pellets were resuspended with 10% FCS and fixed 
by adding an equal volume of 4% formaldehyde (Sigma-Aldrich) and mixed for 10 min at room 
temperature while shaking. Fixation was quenched using 1.425 M glycine (Merck) on ice and 
immediately centrifuged at 400g for 8 min. Pelleted cells were then resuspended in lysis buffer 
(50 mM Tris, pH 7.5; 150 mM NaCl; 5 mM EDTA; 0.5% NP-40; 1.15% Triton X-100; protease 
inhibitors (Roche)), and nuclei were pelleted again by centrifugation at 750g for 5min. 
The pellet was washed with 1x DpnII buffer, resuspended in 50µl 0.5% SDS and incubated for 
10min at 62°C. After that 145µl water and 25µl 10% Triton (Sigma) was added to quench the 
SDS. After a 37°C incubation, 25µl DpnII buffer and 100U DpnII was added. The digestion 
reaction was incubated for 2h at 37°C, after 1h another 10U were added. After the digestion, 
DpnII was inactivated at 65°C for 20min. 
The digested sticky ends were filled up with 10mM dNTPs (without dATP) and 0.4mM biotin-
14-dATP (Life Technologies) and 40U DNA Pol I, Large Klenow  (New England BioLabs, Inc. 
(NEB), Ipswich, MA) at 37°C for 90min. Biotinylated blunt ends were then ligated using a 
ligation reaction (663µl water, 120µl 10X NEB T4 DNA ligase buffer (NEB), 100µl 10% Triton 
X-100 (Sigma), 12µl 10mg/ml BSA and 2400U of T4 DNA liagse (NEB)) overnight at 16°C  
with slow rotation. 
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The 3C library was then sheared using a Covaris sonicator (duty cycle: 10%; intensity: 5; cycles 
per burst: 200; time: 6 cycles of 60 s each; set mode: frequency sweeping; temperature: 4–7 °C). 
After sonication, religated DNA was pulled down using 150µl of 10mg/ml Dynabeads 
Streptavidin T1 beads (Thermo Fisher) according to the supplier’s recommendation. Sheared 
and pulled down DNA was treated using a 100µl end-repair reaction (25mM dNTPs, 50U NEB 
PNK T4 Enzyme, 12U NEB T4 DNA polymerase, 5U NEB DNA pol I, Large (Klenow) 
Fragment, 10X NEB T4 DNA ligase buffer with 10mM ATP) and incubated for 30min at 37°C. 
Universal sequencing adaptor were added using the NEBnext Ultra DNA Library Kit (NEB) 
according to the supplier’s recommendation. Samples were sequenced with Ilumina Hi-Seq 
technology according to standard protocols and 75bp PE mode. 200 million reads were 
generated for IMR-5/75, 5 million reads per sample were generated for all other cell lines. 
FASTQ files were processed using the Juicer pipeline v1.5.6, CPU version34, which was set up 
with BWA v0.7.1735 to map short reads to reference genome hg19, from which haplotype 
sequences were removed and to which the sequence of Epstein-Stein-Barr Virus 
(NC_007605.1) was added. Replicates were processed individually. Mapped and filtered reads 
were merged afterwards. A threshold of MAPQ≥30 was applied for the generation of Hi-C 
maps with Juicer tools v1.7.534. Knight-Ruiz normalization of Hi-C signal was used for Hi-C 
maps. Virtual 4C signal for the MYCN locus was generated by the mean Knight-Ruiz-
normalized Hi-C signal across three 5kb bins (chr2:16,075,000-16,085,000). 
 
4C-seq 
4C-seq libraries were generated as described before26, using a starting material of 5x106 – 1x107 
cells. The fixation and lysis were performed as described in the Hi-C section. For the MYCN 
promotor viewpoint, 1.6 µg DNA was amplified by PCR (Primer 1 5’- 
GCAGAATCGCCTCCG-3’, Primer 2 5’-CCTGGCTCTGCTTCCTAG-3’). For the viewpoint, 
4bp cutters were used. DpnII (NEB) was used as first cutter and Csp6I (NEB) as second cutter. 
All samples were sequenced with the HiSeq 2500 (Illumina) technology according to standard 
protocols and with 8 million reads per sample. 
Reads were pre-processed, filtered for artefacts and mapped to the reference genome  GRCh37 
using BWA-MEM as described earlier26. After removing the viewpoint fragment as well as 1.5 
kb up- and downstream of the viewpoint the raw read counts were normalized per million 
mapped reads (RPM) and a window of 10 fragments was chosen to smooth the profile. 
 
Whole-genome sequencing 
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Cells were harvested and DNA was extracted using the NucleoSpin Tissue kit (Macherey-Nagel 
GmbH & Co. KG, Düren, Germany). Libraries for whole genome sequencing were prepared 
with the NEBNext Ultra II FS DNA Library Prep Kit for Illumina (New England BioLabs, Inc., 
Ipswich, MA). Libraries were sequenced on a NovaSeq S1 flow cell (Illumina, Inc., San Diego, 
CA) with 2x150bp paired-end reads. Quality control, adapter trimming, alignment, duplicate 
removal as for ChIP-seq data. Copy number variation was called (Control-FREEC36 11.4 with 
default parameters). Structural variants were called using SvABA37 (1.1.1) in germline mode 
and discarding regions in a blacklist provided by SvABA 
(https://data.broadinstitute.org/snowman/svaba_exclusions.bed).  
 
Nanopore Sequencing 
Cells were harvested and high molecular weight DNA was extracted using the MagAttract 
HMW DNA Kit (Qiagen N.V., Venlo, Netherlands). Size selection was performed to remove 
fragments <10 kilobases (kb) using the Circulomics SRE kit (Circulomics Inc., Baltimore, 
MD). DNA content was measured with a Qubit 3.0 Fluorometer (Thermo Fisher) and sample 
quality control was performed using a 4200 TapeStation System (Agilent Technologies, Inc., 
Santa Clara, CA). Libraries were prepared using the Ligation Sequencing Kit (SQK-LSK109, 
Oxford Nanopore Technologies Ltd., Oxford, UK) and sequenced on a R9.4.1 MinION flowcell 
(FLO-MIN106, Oxford Nanopore Technologies Ltd., Oxford, UK). Quality control was 
performed using NanoPlot 1.0.0. For the NGP cell line, DNA was extracted with the 
NucleoSpin Tissue kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany) and libraries 
prepared using the ONT Rapid Kit (SQK-RBK004, Oxford Nanopore Technologies Ltd., 
Oxford, UK). Guppy 2.3.7 (Oxford Nanopore Technologies Ltd., Oxford, UK) was used for 
basecalling with default parameters. For de novo assembly, Flye 2.4.238 was run in 
metagenomics assembly mode on the unfiltered FASTQ files with an estimated genome size of 
1Gb. Contigs were mapped back to hg19 using minimap2 2.16 with parameter -ax asm5. 
Assembly results were visualized with Bandage 0.8.1 (https://rrwick.github.io/Bandage) and 
Ribbon (no version available, https://github.com/MariaNattestad/Ribbon). CpG methylation 
was called from the unfiltered raw FAST5 files using Megalodon 0.1.0 (Oxford Nanopore 
Technologies Ltd., Oxford, UK).  
 
Fluorescence in situ hybridization  
Cells were grown to 200,000 per well in six-well plates and metaphase-arrested using Colcemid 
(20µl/2ml; Roche #10295892001) for 30min-3h, trypsinized, centrifuged (1000rpm/10min) 
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washed and pelleted. 5ml 0.4% KCl (4°C; Roth #6781.1) was added to the pellet and incubated 
for 10min. 1ml KCl and 1ml MeOH/acetic acid 3:1 (Roth #4627.2, #KK62.1) was added drop-
wise. 2/5/5ml of MeOH/acetic acid were added in between centrifugation steps (1000 
rpm/10min) respectively. Suspension was dropped on a slide from a height of 40cm. Slides 
were washed with PBS (Gibco, #70011036) and digested for 10min in 0,04% pepsin solution 
in 0,001N HCl. Slides were washed in 0.5x SSC, dehydrated with 70%/80%/100% EtOH (3min 
each) and air-dried. 10µl of the probe (Vysis LSI N-MYC; #07J72-001; Lot #472123; Abbott 
Laboratories, Abbott Park, IL) were added and coverslips fixed on the slide. Slides were 
incubated at 75°C for 10min and at 37°C over night. The coverslip was removed and the slide 
washed in 0.4xSSC/0.3% IGEPAL (CA-630, #18896, Sigma-Aldrich Inc.) for 3min at 60°C 
and 2xSSC/0.1% IGEPAL for 3min at RT. 5µl DAPI (Vectashield, #H-1200, Vector) was 
added. A coverslip was added and fixed with nail polish.  
 
Enhancer calling  
MYCN-expressing cell lines were defined as cell lines with sizeFactor normalized expression 
of 100 or above based. We identified enhancer candidate regions in a ±500kb window around 
MYCN. We focused on regions with a H3K27ac peak in the majority of MYCN-expressing, non-
MYCN-amplified cell lines, i.e. three or more. If the gap between two such regions was less 
than 2kb, they were joined. These regions were then ranked by the maximum difference in 
H3K27ac signal fold change between non-amplified, MYCN-expressing and non-expressing 
cell lines. We chose the five highest-ranking regions as candidate regulatory elements.  
Enhancer regions were screened for transcription factor binding sequences from the 
JASPAR2018 (http://jaspar2018.genereg.net/) and JASPAR2020 
(http://jaspar2020.genereg.net/) database using the TFBSTools (1.20.0) function matchPWM 
with min.score=’85%’. CRC-driven super enhancers were defined as all regions with a LILY-
defined super enhancer in MYCN-expressing, non-MYCN-amplified cell lines that overlapped 
with a GATA3, HAND2 or PHOX2B peak in CLB-GA. 
 
Analysis of copy number data 
Public data was downloaded. Samples that were described as MYCN-amplified in the metadata 
but did not show MYCN amplification in the copy number profile were excluded. In order to 
generate an aggregate copy number profile, the genome was binned in 10kb bins and number 
of samples with overlapping amplifications was counted per bin.  Randomized copy number 
profiles were generated by randomly sampling one of the original copy number profiles on 
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chromosome 2 and randomly shifting it such that MYCN is still fully included within an 
amplified segment. For class I-specific shuffling, e4 had to be included as well; for class II-
specific shuffling, e4 was never included on the randomly shifted amplicon. Empirical P-values 
for significant co-amplification were derived by creating 10,000 randomized datasets with each 
amplicon randomly shifted and comparing the observed co-amplification frequency to the 
distribution of co-amplification frequencies in the randomized data. Empirical P-values were 
always one-sided and adjusted for multiple comparisons using the Benjamini-Hochberg 
procedure. 
 
Amplicon reconstruction  
All unfiltered SvABA structural variant calls were filtered to exclude regions from the 
ENCODE blacklist39 and small rearrangements of 1kb or less. As we were only aiming at the 
rearrangements common to all amplicons, we only considered breakpoints with more than 50 
variant-support reads (‘allele depth’). gGnome40 was used to represent these data as a genome 
graph with nodes being breakpoint-free genomic intervals and edges being rearrangements 
(‘alternate edge’) or connections in the reference genomes (‘reference edge’). We considered 
only nodes with high copy number, i.e. with a mean whole-genome sequencing coverage of at 
least 10-fold the median coverage of chromosome 2. Then, reference edges were removed if its 
corresponding alternate edge was among the 25% highest allele-depth edges. The resulting 
graph was then searched for the circular, MYCN-containing walk that included the highest 
number of nodes without using any node twice. We used gTrack 
(https://github.com/mskilab/gTrack) for visualization. For custom Hi-C maps of reconstructed 
amplicon sequences of CHP-212 and IMR-5-75, respectively, the corresponding regions from 
chromosome 2 were copied, ordered, oriented and compiled according to the results from the 
amplicon reconstruction and added to the reference genome. Additionally, these copied regions 
were masked with ‘N’ at the original locations on chromosome 2 to allow a proper mapping of 
reads to the amplicon sequence. The contribution of Hi-C di-tags from these regions on 
chromosome 2 to the amplicon Hi-C map is expected be minor, because the copy number of 
amplicons is much higher than the number of wild type alleles. Juicebox v1.11.08 was used to 
visualize Hi-C maps with a bin size of 5 kb and Knight-Ruiz normalization41-43.  
 
Data availability 
Copy number data for high-risk neuroblastoma were downloaded from 
https://github.com/padpuydt/copynumber_HR_NB/. Sequencing data supporting the findings 
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of this manuscript is available at the Gene Expression Omnibus under accessions GSE90683, 
GSE80152, GSE24447 and GSE28874. Sequencing data for primary neuroblastoma samples is 
available at the European Genome-Phenome archive under accessions EGAS00001001308 and 
EGAS00001004022. Corresponding BigWig und narrowPeak files can be downloaded from 
https://data.cyverse.org/dav-anon/iplant/home/konstantin/helmsaueretal/. An accompanying 
UCSC genome browser track hub is provided for ChIP-seq and ATAC-seq data visualization 
(https://de.cyverse.org/dl/d/27AA17DA-F24C-4BF4-904C-62B539A47DCC/hub.txt). All 
other data is available from the corresponding authors upon reasonable request.  
 
Code availability 
Code is available at https://github.com/henssenlab/MYCNAmplicon. 
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Figure 1. Five enhancers are specifically found in MYCN-expressing neuroblastoma cells. 
a, H3K27ac ChIP-seq fold change over input (left) and size-factor normalized MYCN 
expression as determined from RNA-seq for 12 non-MYCN-amplified neuroblastoma cell lines 
(MYCN-expressing, red; non MYCN-expressing, blue). b, Aggregated H3K27ac signal of 
MYCN-expressing compared to non-expressing cells (top; MYCNp, MYCN promotor; e1-e5, 
MYCN-specific enhancers). PHOX2B, GATA3 and HAND2 core regulatory circuit 
transcription factor ChIP-seq in a MYCN-expressing neuroblastoma cell line (green, CLB-GA).  
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Fig. 2. MYCN-specific enhancer e4 is significantly co-amplified with MYCN and retains 
functional enhancer characteristics after amplification.  a, Co-amplification frequency of 
the immediate MYCN neighborhood measured using copy number profiles from 240 MYCN-
amplified neuroblastomas (solid line) compared to the expected co-amplification frequencies 
for randomized MYCN-containing amplicons (dashed line). b, Upset plot showing the co-
amplification patterns of all five MYCN-specific local enhancers identified in neuroblastoma. 
c, Enrichment for co-amplification with MYCN of genomic regions on 2p (red, co-amplification 
more frequent than expected by chance; blue, co-amplification less frequent than expected by 
chance).  
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Fig. 3. Two classes of MYCN amplicons can be identified in neuroblastoma. Schematic 
representation of class I (a) and class II (b) MYCN amplicons. c, Copy number profile, ATAC-
seq, H3K27ac ChIP-seq, H3K4me1 ChIP-seq and 4C (MYCN promotor as the viewpoint) for 
two neuroblastoma cell lines with class I amplicons, co-amplifying the e4. d, Copy number 
profile, ATAC-seq, H3K27ac ChIP-seq, H3K4me1 ChIP-seq and 4C (MYCN promotor as the 
viewpoint) for two neuroblastoma cell lines class II amplicons, not co-amplifying e4. e, Number 
of non-contiguous amplified fragments in class I vs. class II MYCN amplicons. d Amplicon 
boundary frequency relative to gene and enhancer positions in class I (blue) vs. class II (red) 
amplicons compared to random amplicon boundary frequencies (dotted lines).   
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Figure 4. Reconstruction and epigenetic markup of class II intra- and extrachromosomal 
circular MYCN amplicons in neuroblastoma cells. a Short-read based reconstruction and 
epigenomic characterization of the MYCN amplicon in IMR-5/75 cells. Top to bottom: Hi-C 
map (color indicating Knight-Ruiz normalized read counts in 25kb bins), virtual 4C (MYCN 
viewpoint, v4C), CTCF ChIP-seq, H3K27Ac ChIP-seq, Amplicon reconstruction, copy number 
profile, super enhancer locations (yellow), gene positions (blue) (scale). b Schematic 
representation of the class II amplicon described in (a), showing ectopic enhancers and insulator 
reshuffling leading to locally disrupted regulatory neighborhoods on the HSR. c Alignment of 
Hi-C reads to the reconstructed MYCN amplicon in IMR-5/75 and positions of genes, local 
MYCN enhancers and CRC-driven super enhancers on the amplicon. d Mapping of the long 
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read sequencing-based de novo assembly of the MYCN amplicon in IMR5/75 on chromosome 
2.  e Short-read based reconstruction and epigenomic characterization of the MYCN amplicon 
in CHP-212 cells. Top to bottom: Hi-C map (color indicating Knight-Ruiz normalized read 
counts in 25kb bins), virtual 4C (MYCN viewpoint, v4C), CTCF ChIP-seq, H3K27Ac ChIP-
seq, Amplicon reconstruction, copy number profile, super enhancer locations (yellow), gene 
positions (blue). f, Schematic representation of the class II amplicon described in (e), showing 
ectopic enhancers and insulator reshuffling leading to locally disrupted regulatory 
neighborhoods on extrachromosomal circular DNA. g Alignment of Hi-C reads to the 
reconstructed MYCN amplicon in CHP-212 and positions of genes, local MYCN enhancers and 
CRC-driven super enhancers on the amplicon. h Mapping of the long read sequencing-based 
de novo assembly of the MYCN amplicon in CHP-212 on chromosome 2.   
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Figure 5. Nanopore long read sequencing allows for the simultaneous characterization of 
amplicon structure and DNA methylation. a, Schematic of experimental approach. b, 
Schematic representation of how Nanopore sequencing facilitates de novo amplicon assembly 
and can be used to simultaneously to detect regulatory elements through DNA methylation 
analysis. c, Composite DNA methylation signal detected using Nanopore sequencing over 
genes expressed at high (blue) vs. low (green) levels. d, Motif analysis based on accessibility 
in regulatory elements co-amplified on MYCN amplicons. e, Amplicon-specific methylation 
pattern detected in three neuroblastoma cell lines using Nanopore sequencing-based DNA 
methylation analysis. 
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Figure 6. Class II amplicons clinically phenocopy class I amplicons. Kaplan Meier survival 
analysis of patients with MYCN-amplified neuroblastoma, comparing single-fragment vs. non-
contiguously amplified MYCN amplicons (a), co-amplification of ODC1 vs. no co-
amplification (b), co-amplification of ALK vs. no co-amplification, and class I amplicons vs. 
class II amplicons (d; N=236 MYCN-amplified neuroblastomas; P- value based on two-sided 
log rank test).  
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Supplementary Fig. 1. Enhancers in MYCN expressing neuroblastoma contain binding 
motifs for core regulatory circuit factors. a H3K27ac ChIP-seq signal (counts per million in 
10bp bins, smoothed in 1kb bins) for seven non-MYCN-expressing neuroblastoma cell lines 
(blue), five MYCN-expressing non-MYCN-amplified neuroblastoma cell lines (red) and 13 
MYCN-amplified neuroblastoma cell lines. b Differential composite H3K27ac signal for 
MYCN-non-expressing vs. MYCN-expressing non-MYCN-amplified cells (difference in the 
group-wise mean fold change H3K27ac vs. input) and H3K27ac ChIP-seq (counts per million 
in 10bp bins, smoothed in 1kb bins)  signal for in vitro differentiated developmental cell types 
(embryonic stem cells, neuroectodermal cells, neural crest cells). c Core regulatory circuit 
factor (PHOX2B, GATA3, HAND2, ISL1, TBX2, ASCL1), MYCN and TEAD4 binding motif 
positions in the MYCN-driving enhancers e1-e5. Only motif hits within the enhancer regions 
are depicted. d MYCN expression for 25 neuroblastoma cell lines as determined by RNA-seq 
(size factor-normalized read counts) classified into no MYCN expression (size factor 
normalized expression lower than 100), MYCN-expressing non-MYCN-amplified cells (size 
factor normalized expression 100 or more) and MYCN-amplified cell lines.  
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Supplementary Fig. 2. Asymmetric amplicon boundaries cannot be explained by 
experimental platform, clinical variables or chromosomal fragile sites. a-e Percent co-
amplification in 10kb bins for MYCN-amplified neuroblastoma (n=240) split by the 
experimental method to measure genomic copy-number (a, Affymetrix SNP array, Agilent 
aCGH platform, Illumina SNP array, NimbleGen aCGH platform), the age quartile of  patients 
(b, 1=lowest quartile, 4=highest quartile), long-term survival (c, defined as survival beyond 
five years post diagnosis) and the genetic factors 17q gain (d) and 1p loss (e). f Amplified 
regions on chromosome 2 (0Mb-40Mb) for primary neuroblastoma (n=240), colored by 
amplicon class (class I amplicons including e4 vs. class II amplicons not including e4)  g 
Percent co-amplification in 10kb bins around MYCN for MYCN-amplified neuroblastoma 
(n=240) and position of common fragile sites on chromosome 2 between 12Mb and 20Mb. 
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Supplementary Fig. 3 H3K27ac ChIP-seq data characteristics on the MYCN amplicon for 
13 MYCN-amplified neuroblastoma cell lines. a Estimated fraction of H3K27ac reads in 
peaks for amplified regions (red) vs. randomly drawn genomic regions of matching size (grey, 
n=30) in 12 MYCN-amplified neuroblastoma cell lines. b Number of peaks for amplified 
regions (red) vs. randomly drawn genomic regions of matching size (grey, n=30) in 12 MYCN-
amplified neuroblastoma cell lines. c Relative H3K27ac peak heights (compared to amplicon 
background) for amplified regions (red) vs. randomly drawn genomic regions of matching size 
(grey, n=30). In all boxplots, boxes depict the median, the upper quartile boundary and the 
lower quartile boundary. Whiskers extends to the largest data point within 1.5-fold of the inter-
quartile range. 
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Supplementary Fig. 4 Long-read nanopore sequencing enables de novo assembly of  
MYCN neighborhoods in neuroblastoma cell lines. a-d Nanopore read length distribution 
(log-transformed) for the neuroblastoma cell lines Kelly (a, n=2,654,406), IMR-5/75 (b, 
n=474,980), CHP-212 (c, n=1,554,048) and NGP (d, n=952,031).  e Nanopore long read-based 
de novo assembly of Kelly cells yields 477 contigs and an overall assembly N50 of 24,929 bp. 
BLAST analysis locates MYCN on a circular 975,932 bp  contig. f Nanopore long read-based 
de novo assembly of IMR-5/75 cells yields 6,265 contigs and an overall assembly N50 of 
91,273 bp. BLAST analysis locates MYCN on a linear 3,201,197 bp contig. g Nanopore long 
read-based de novo assembly of CHP-212 cells yields 21,264 contigs and an overall assembly 
N50 of 113,845 bp. BLAST analysis locates MYCN on a circular 1,705,218 bp contig. h 
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Nanopore long read-based de novo assembly of NGP cells yields 6,550 contigs and an overall 
assembly N50 of 60,981 bp. BLAST analysis locates MYCN on a linear 623,907 bp contig.    
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Supplementary Fig. 5 De novo assembly confirms close co-amplification of MYCN and e4 
in Kelly and NGP. Mapping of the de novo assembled MYCN-containing contig to hg19 in 
Kelly (a) and NGP (b) cells. Positions of MYCN and e4 are marked on the contig and in the 
reference genome. Note that the Kelly contig is circular such that the shortest distance from e4 
to MYCN spans the contig circle junction.  
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Supplementary Fig. 6 Enhancer hijacking and neo-TAD formation on the MYCN 
amplicon in IMR-5/75 and CHP-212 Regions that contribute to neo-TAD formation are 
depicted for IMR-5/75 (a) and CHP-212 (b). Top to bottom: Gene bodies, Copy Number, 
ATAC-seq, H3K27ac ChIP-seq, H3K4me1 ChIP-seq, CTCF ChIP-seq, RAD21 ChIP-seq (only 
available for IMR-5/75), virtual 4C with MYCN as the viewpoint (mean Knight-Ruiz 
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normalized interaction frequency of three 5kb bins (chr2:16,075,000-16,085,000) around 
MYCN), the aggregate H3K27ac signal over 7 MYCN-expressing non-MYCN-amplified 
neuroblastoma celllines (mean fold change over input),  GATA3 ChIP-seq, PHOX2B ChIP-seq 
and HAND2 ChIP-seq (all CRC transcription factors in the neuroblastoma cell lines CLB-GA). 
ChIP-seq and ATAC-seq is depicted as counts per million in 10bp bins, smoothed in 1kb bins.  
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Supplementary Fig. 7 Fluorescence in situ hybridization of MYCN ecDNA in CHP-212 
and MYCN HSRs in IMR-5/75, Kelly and NGP a Fluorescence in situ hybridization (FISH) 
of CHP-212 metaphase spreads with a MYCN probe (green) and a probe for the chromosome 2 
centromere (red). Arrowheads point to MYCN ecDNA. b, c FISH of metaphase spreads in IMR-
5/75 with a MYCN probe (green), a chromosome 2 centromere (red) and a chromosome 12 paint 
(red) d FISH of metaphase spreads in Kelly cells with a MYCN probe (red) and chromosome 
17 paint (green). e FISH of NGP metaphase spreads with a MYCN probe (green) and a probe 
for the chromosome 2 centromere (red).  
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